Short-acting beta agonist (SABA) inhalers account for 70% of the total carbon footprint of all inhalers in the UK and uncontrolled asthma has a higher carbon impact than controlled asthma. Frequent SABA use is a feature of uncontrolled asthma and is associated with increased risk of asthma attacks. Reducing SABA over-use can achieve important outcomes for both patients and the environment.
SENTINEL is a collaboration between NHS providers, the University of Hull and AstraZeneca. Through implementation of a co-designed intervention, SENTINEL identifies and addresses SABA over-use with the aim of improving asthma outcomes and reducing the environmental impact of asthma.
Presented in conjunction with Dr Michael Crooks (Hull & East Yorkshire Teaching Hospitals NHS Trust) and Astrazeneca
This session is free to staff from NHS organisations and those working within the AHSN Networks.
This session will cover:
• Introduction to the SENTINEL programme a multifaceted approach which aims to reduce the use of SABA inhalers, and encourage the prescribing of preventer medication, and where appropriate Dry Powder Inhalers.
• Introduction to the SENTINAL Plus resources for clinicians including:
Health Care Professional Education.
Implementation of ‘gold standard’ prescribing practice.
Targeted asthma reviews to identify those patients more at risk.
Patients support and education and
An opportunity for real time data monitoring and reporting of asthma care metrics.
Since the introduction of the SENTINEL programme, data from the first PCN’s engaged has shown a reduction in inhaler prescription by nearly 9,000 units which equates to an offset of nearly 250,000 kg eCO2 emissions (this is equivalent to more than 300 transatlantic flights).